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E-mail address: shirou@affrc.go.jp (S. Mohri).Characteristic differences of prions may account for the conformational diversity of the pathogenic
isoform of prion protein (PrPSc). Here, we applied a protein detection procedure by using ﬂuores-
cent-labelled peptides for detecting PrPSc. Five prion protein (PrP) related peptides were found to
change signiﬁcantly their ﬂuorescent intensities with prion-affected animal samples. Their reactiv-
ity was different among atypical L-BSE, classical BSE and scrapie. The pull-down assay revealed that
they precipitated PrPSc speciﬁcally. These ﬁndings suggest that ﬂuorescent intensity changes depend
on peptide–PrPSc binding. This novel approach may distinguish the ﬁne structural differences in
PrPSc, which were not detected by the pull-down assay.
Structured summary of protein interactions:
PrP-peptides HPP01, 02, 03, 06, 11 physically interact with PrPSc of L-type atypical and classical BSEs,
and scrapie by pull down
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction gest that prion identity is encoded by the conformation of PrPSc,Prion diseases, also called transmissible spongiform encepha-
lopathies (TSEs), are fatal neurodegenerative disorders, including
bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep
and goats, chronic wasting disease (CWD) in cervids, and
Creutzfeldt–Jakob disease (CJD) in humans [1]. The pathogenic iso-
form of prion protein (PrPSc) is generated by post-translational
modiﬁcation of the cellular prion protein PrPC, and is considered
a major component of the infectious agent, prion [1]. Although PrPC
and PrPSc have identical amino acid sequence, their secondary and/
or tertiary structures differ. Furthermore, prions consist of multiple
types that are classiﬁed by incubation periods and lesion proﬁles in
inbred mice [2]. Some prions may also differ in their PrPSc proper-
ties, e.g. different electrophoretic mobilities [3], relative glycoform
ratios [4], N-terminal ends of proteinase K (PK) digested PrPSc [5],
immunoreactivities against conformational-speciﬁc antibodies
[6,7], and stabilities against chaotropes [8]. These differences sug-chemical Societies. Published by E
rion protein; PrPSc, disease-
ephalopathy; C-BSE, classical
ﬂuorescence indexbut little research has been done to conﬁrm this.
To differentiate among PrPSc conformers, it is necessary to
develop a new strategy involving the use of probes that speciﬁcally
bind to PrPSc. PrPC fused with immunoglobulin [9] and PrP-grafted
antibodies [10–12] speciﬁcally bind to PrPSc. Furthermore, several
PrP synthetic peptides were shown to bind to PrPSc [13]. These
results may indicate that PrPC and PrP peptides bind to PrPSc, and
therefore, could be developed as novel probes to classify PrPSc
conformers.
Luminescent conjugated polymers (LCPs) could distinguish
prion strains by their ﬂuorescence spectra [14]. Non-covalent bind-
ing to proteins constrains the rotational freedom of LCPs, and thus
alters their spectral properties in a conformation-dependent man-
ner [15,16]. Monitoring the changes in ﬂuorescence could be a sen-
sitive method for detecting conformational variability in prion
strains. A similar procedure has been reported for detecting
peptide–protein binding by using ﬂuorescence-labelled structur-
ally designed peptides [17–20]. In this assay, the altered intensity
of ﬂuorescence represented the peptide–protein interactions.
Applying this technique for the analysis of prion differentiation,
we now report that different peptides reacted with PrPSc derived
from scrapie and those derived from the two types of BSE. Changes
in ﬂuorescence may represent a ﬁne peptide–PrPSc interaction,
which was not detected by the protein-pull down assay.lsevier B.V. All rights reserved.
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2.1. Peptides
We synthesised a set of PrP-related peptides (HPP01–25) that
were composed of 15 amino acids, shifted by 10 amino acids,
and covered the entire human PrP sequence (GenBank Acc. No.
AAH12844). Since the peptides corresponding to the N-terminal
signal sequence (HPP01 and 02) or the C-terminal glycosylphos-
phatidylinositol (GPI) anchor signal (HPP24 and 25) were less
soluble, an additional Lys-Lys-Arg (KKR) sequence was attached
to their C-termini. The HPP06-s was generated as a randomly
scrambled HPP06 peptide. Sequence details are shown in Table 1.
The N-terminal end of the peptide was conjugated with an addi-
tional Gly residue as a spacer, along with either a ﬂuorescent dye
(TAMRA) for ﬂuorescence-based detection or biotin for the pull-
down assay. The C-terminal end of the peptide has an amide group.
All peptides were synthesised by the solid-phase method using the
Fmoc strategy [21].
2.2. Animals and prions
All animal experiments were reviewed by the committee deal-
ing with Ethics in Animal Experiments at National Institute of Ani-
mal Health. The animals were sacriﬁced during the clinical stage of
prion disease. The brains of mice (Slc:ICR) infected with the mouse
scrapie strain (Chandler) [22] were used. The brainstems of sheep
experimentally infected with scrapie [23] and cattle experimen-
tally infected with classical BSE (C-BSE) [24] or L-type BSE (L-
BSE) [25,26] were used. The brains of uninfected mice (Slc:ICR),
and the brainstems of healthy sheep and cattle were used as neg-
ative controls.Table 1
Fluorescent-peptide assay results.
Peptide ID No. of residuesb Amino acid sequencec,d
HPP01 1–12 MANLGSWMLVLFKKR
HPP02 11–25 LFVATWSDLGLSKKR
HPP03 21–35 LSKKRPKPGGWNTGG
HPP04 31–45 WNTGGSRYPGQGSPG
HPP05 41–55 QGSPGGNRYPPQGGG
HPP06 51–65 PQGGGGWGQPHGGGW
HPP07 61–75 HGGGWGQPHGGGWGQ
HPP08 71–85 GGWGQPHGGGWGQPH
HPP09 81–95 WGQPHGGGWGQGGGT
HPP10 91–105 QGGGTHSQWNKPSKP
HPP11 101–115 KPSKPKTNMKHMAGA
HPP12 111–125 HMAGAAAAGAVVGGL
HPP13 121–135 VVGGLGGYVLGSAMS
HPP14 131–145 GSAMSRPIIHFGSDY
HPP15 141–155 FGSDYEDRYYRENMH
HPP16 151–165 RENMHRYPNQVYYRP
HPP17 161–175 VYYRPMDEYSNQNNF
HPP18 171–185 NQNNFVHDSVNITIK
HPP19 181–195 NITIKQHTVTTTTKG
HPP20 191–205 TTTKGENFTETDVKM
HPP21 201–215 TDVKMMERVVEQMSI
HPP22 211–225 EQMSITQYERESQAY
HPP23 221–235 ESQAYYQRGSSMVLF
HPP24 231–242 SMVLFSSPPVILKKR
HPP25 242–253 LLISFLIFLIVGKKR
HPP06-s QGGWPPGQGWGGHGG
a +, Signiﬁcant; , not signiﬁcant; n.d, not determined.
b The number of residues is equivalent to human PrP sequence.
c Cysteine residue was substituted by serine residue for further application (double u
d The basic amino acid residues (K and R) are underlined.2.3. Fluorescent peptide assay
Brain samples were homogenised in 4 volumes of 10 mM so-
dium phosphate buffer (pH 7.0) at 3000 rpm for 2 min by using a
Multi-beads Shocker (Yasui-Kikai, Osaka, Japan) to produce a 20%
(w/v) brain homogenate. Equal volumes of the brain homogenate
and ﬂuorescence-labelled peptide (2% (w/v) or 2 lM in 10 mM so-
dium phosphate buffer) were mixed in one well of Black Maxisorp
Fluoronunc Cert. (ThermoFisher Scientiﬁc, Roskilde, Denmark), and
incubated for 30 min at room temperature. Fluorescence was mea-
sured using an ARVO 1420 Multilabel Counter (Wallac-Perkin
Elmer, Waltham, MA) with the excitation and emission wave-
lengths of 560 and 600 nm, respectively. To focus on the difference
in the ﬂuorescence of the prion-affected and control samples, the
ﬂuorescence index (FI) was calculated as follows: FI = (Inten-
sityprionIntensitycontrol)/Intensitycontrol  100 (%). The FI was indi-
cated by an absolute value. Column statistical analyses were
used to verify the results obtained. An FI at least 1.5 times higher
than the 99% conﬁdence interval value was considered signiﬁcant.
Fluorescence intensities of HPP18, HPP19, and HPP25 were minus-
cule, and therefore, the values were excluded from analyses.
2.4. Peptide pull-down assay
Biotinylated peptides were attached to streptavidin-coated
magnetic beads (M-280; Veritas, Tokyo, Japan) for 2 h in TNB buf-
fer (10 mM Tris, 150 mM NaCl, 0.1% BSA, pH 7.4). Beads were
washed with TNB buffer, and then mixed with mouse, sheep, or
cattle brain homogenate for 2 h at room temperature. Reactants
bound to beads were magnetically pulled down. Beads were
washed with TNB buffer containing 1% Triton X-100. They were
then treated with or without 40 lg/ml of proteinase K (PK) atFluorescent-peptide assaya
Mouse Sheep Cattle
Scrapie C-BSE L-BSE
  + 
  + 
   +
   
   
+ +  
   
   
   
   
   +
   
   
   
   
   
   
n.d n.d n.d n.d
n.d n.d n.d n.d
   
   
   
   
   
n.d n.d n.d n.d
 n.d n.d n.d
nderlined).
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SDS loading buffer, and subjected to Western blot analysis. PrP
was detected by a horseradish peroxidase-conjugated anti-PrP
monoclonal antibody, T2 [27]. Blots were developed using a chemi-
luminescence substrate (Pierce SuperSignal; ThermoFisher Scien-
tiﬁc, Rockford, IL).
3. Results
3.1. Analysis of peptide reactivity with brain homogenates using the
ﬂuorescent peptide assay
Fluorescent peptide assay revealed that HPP06 signiﬁcantly
reacted with the brain homogenates from both scrapie-affected
mice and sheep, but not with those from cattle affected with
C-BSE and L-BSE (Table 1 and Supplementary Fig. 1A and B). Alanine
scan analyses showed that single amino acid substitutions in the
HPP06 sequence abolished the FI values (Fig. 1A and B, respectively).
Furthermore, a randomly scrambled HPP06 sequence (HPP06-s) did
not show reactivity (Fig. 1A).
In contrast, HPP01 and HPP02 speciﬁcally reacted with the brain
homogenates from the C-BSE-affected cattle. (Table 1 and Supple-
mentary Fig. 1C). Furthermore, HPP03 and HPP11 also showed spe-
ciﬁc reactions with the brain homogenates from the L-BSE-affected
cattle (Table 1 and Supplementary Fig. 1D). Other peptides showed
no signiﬁcant reactions with the examined samples.
3.2. Analysis for peptide–PrPSc binding using the pull-down assay
Five peptides, which tested positive in the ﬂuorescent peptide
assay, were subjected to the pull-down assay. Five peptides
showed cross-reactivity with the examined prion-affected brain
homogenates, and bound to PrP in the scrapie-, C-BSE-, and
L-BSE-affected brain samples (Fig. 2A–D, lanes 3–7), but did not
bind to PrP in the brain samples from normal mice, sheep and cat-
tle (Fig. 2A–C, lanes 19–23). Precipitated PrP showed partial resis-
tance to PK digestion and converged to the 19–28-kDa form of PrP,
which was identical to the PK-digested PrPSc (PrPcore) (Fig. 2A–D,
lanes 11–15). HPP13, which showed no reactivity in the ﬂuores-Fig. 1. Alanine scan peptides and an HPP06 scrambled peptide indicated amino acid
residues were substituted by alanine. The original (ori) and alanine scan peptides of
HPP06 were subjected to ﬂuorescent peptide assay with the brain homogenates
from scrapie-affected mice (A) or sheep (B). Randomly scrambled HPP06 (HPP06-s)
was also examined with the brain homogenate of scrapie-affected mice. Columns
represent the mean ± S.E.M. values (n = 3 or 4 for alanine scan peptides or a
scrambled peptide, respectively).cent peptide assay, did not bind to any PrP in the pull-down assay
(Fig. 2A–D, lanes 8 and 16).
4. Discussion
This study showed that 5 ﬂuorescence-labelled peptides
(HPP01, HPP02, HPP03, HPP06, and HPP11) displayed altered ﬂuo-
rescence when mixed with prion-affected animal samples. Previ-
ously, speciﬁc peptide–protein interactions were detected by
altered ﬂuorescence intensities of the probes attached to synthes-
ised peptides [17–20]. To conﬁrm peptide–PrP binding, a pull-
down assay was executed. PrP was precipitated from the prion-
infected, but not from the normal animal brains. Furthermore,
the precipitated PrP showed partial resistance to PK digestion,
and PrP was converged to the PrPcore with this treatment. Our
results suggest that 5 peptides speciﬁcally bound to PrPSc in the
pull-down assay, and it might eventually alter ﬂuorescence in this
peptide assay.
The 5 peptides found in this study are classiﬁed into three sub-
regions: HPP01–03 (PrP1–35), HPP06 (PrP51–65), and HPP11
(PrP101–115). It has been shown that PrP19–30 and PrP100–111
regions directly interact with PrPSc frommultiple species. Although
this interaction is not dependent on the sequence, amino acid com-
position—especially the presence of multiple positively charged
basic amino acid residues (K/R)—affects the interaction [13].
HPP01–03 and HPP11 partially overlapped these sub-regions and
contained multiple K/R residues. HPP01 and HPP02 consist of a sig-
nal sequence that is deleted in a mature protein, and also possess a
KKR sequence. Our results emphasise the importance of basic ami-
no acids in interactions with PrPSc. In the pull-down assay, these 4
peptides detected multiple PrPSc from different prion types, similar
to the ﬁndings of previous studies [13].
In contrast, the ﬂuorescent peptide assay showed different reac-
tivities with different prions (Table 2). While HPP01 and HPP02
reacted with the brain homogenates of C-BSE, but not with that
of L-BSE, HPP03 and HPP11 displayed opposite reactivities. This
suggests that PrPSc of C-BSE and L-BSE were successfully differen-
tiated using this novel assay. Moreover, this result indicates that
the K/R residues could bind and pull down PrPSc, but this binding
was not sufﬁcient to alter the intensity of ﬂuorescence. Amino acid
sequences associated with the K/R residues may have contributed
to these results.
Another peptide (HPP06) corresponds to the octa-repeat region
and lacks the K/R residues. It was thought that the N-terminal
region of PrP is unstructured, with considerable backbone ﬂexibil-
ity [28]. A model suggested that the octa-repeat region is con-
strained by four Cu2+-coordinating histidines into a compact
structure in PrPC [29]. Evidence from several studies shows that
the octa-repeat sequences may play a role in propagating prions
[30,31]. A recent study indicated that several epitopes located in
the octa-repeat region of PrPSc are exposed in PrPC [32]. This study
suggested that the octa-repeat region of PrPSc is conformationally
different from that of PrPC. Others postulated that this region
may contribute the intermolecular and intramolecular interactions
required for PrPSc propagation [33]. HPP06 may mimic the binding
domain of PrPC with PrPSc. Furthermore, this sequence may not be
included in PrPC–PrPC interactions. In the ﬂuorescent peptide as-
say, HPP06 clearly discriminated the PrPSc of scrapie from that of
BSEs, further suggesting that the octa-repeat region of scrapie PrPSc
differs from that of BSE PrPSc. Randomly scrambled peptide
(HPP06-s) and alanine scan experiments revealed that ﬂuorescence
changes associated with HPP06 was a sequence-dependent phe-
nomenon. Moreover, negative results of ﬂuorescent peptide assay
for other peptides (HPP04, HPP05, and HPP07–09) located in the
octa-repeat region also support the importance of the entire
HPP06 sequence for this reaction.
Fig. 2. Peptide pull-down assay with the brain homogenates from mouse scrapie (A), sheep scrapie (B), C-BSE-infected cattle (C), and L-BSE-infected cattle (D). No peptide
(lanes 2, 10, and 18), HPP01 (lanes 3, 11, and 19), HPP02 (lanes 4, 12, and 20), HPP03 (lanes 5, 13, and 21), HPP06 (lanes 6, 14, and 22), HPP11 (lanes 7, 15, and 23), and HPP13
(lanes 8, 16, and 24) were examined in the pull-down assay. Aliquots of input (lanes 1, 9, and 17) was equivalent to 1/2 volume (A and B) or 1/10 volume (C and D).
Precipitants and aliquots of input were treated without (panels 1–8) or with PK (lanes 9–16), followed by Western blotting using anti-PrP antibody. Control animal brain
homogenates of mice (A), sheep (B), and cattle (C) were also examined (lanes 17–24). Molecular mass markers (kDa) are shown on the left.
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PrPSc conformation [3–8]. The combinatorial use of ﬂuorescent
peptides in our novel assay could distinguish between L-BSE and
C-BSE, and scrapie PrPSc. Fluorescent peptides may recognise ﬁne
structures, which may underlie PrPSc conformational differences.
The precise mechanism of the changes in ﬂuorescence is unclear;Table 2
Peptides reactivities in the ﬂuorescent-peptide assay versus pull-down assay.
Peptide ID Fluorescent-peptide assaya Pull-down assayb
Scrapie C-BSE L-BSE Scrapie C-BSE L-BSE
HPP01  +  + + +
HPP02  +  + + +
HPP03   + + + +
HPP06 +   + + +
HPP11   + + + +
HPP13      
a Fluorescent-peptide was reacted (+) or not reacted () with brain homogenates
from prion-affected animals in ﬂuorescent-peptide assay.
b Biotinylated peptide was bound (+) or not bound () to PrPSc in peptide pull-
down assay.however, we conﬁrmed that immobilised peptide was capable of
these changes (data not shown). This result excludes the possibility
that the changes in ﬂuorescence were derived from ﬂuorescence-
quenching effect caused by peptide accumulation on PrPSc aggre-
gates, but it may support the idea that these changes resulted from
conformational changes in binding peptides. This might account
for the different reactivities of HPP01/02 and HPP03 with PrPSc of
BSEs. The peptide binds to PrPSc via an electrically charged KKR
cluster. It causes attracting/repulsive forces between PrPSc and
the peptide in accordance with the hydrophobic/hydrophilic prop-
erty of the peptide. It subsequently triggers a conformational
change in the peptide, followed by a change in ﬂuorescence. In
addition, the distance from the KKR cluster to the TAMRA dye is
different between HPP01/02 and HPP03. This difference might also
reﬂect their conformational change. Although HPP01/02 did not
correspond to the mature PrP, their sequence may be adequate
for detecting PrPSc of C-BSE. In contrast, HPP03/11 may have a
structure suitable for detecting PrPSc of L-BSE. During this analysis,
no treatments with detergents or chaotropes that could inﬂuence
the constructive nature of proteins were performed; the results
of the present study represent the native conformation of PrPSc.
We showed here the potential of this novel approach for prion dif-
ferentiation and structural analysis of authentic PrPSc.
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